Advertisement

Tumor Biology

, Volume 37, Issue 9, pp 11723–11732 | Cite as

Ubiquitin-Conjugating Enzyme E2T is an Independent Prognostic Factor and Promotes Gastric Cancer Progression

  • Hao Yu
  • Pei Xiang
  • Qi Pan
  • Yijiao Huang
  • Nanlan Xie
  • Weimin Zhu
Original Article

Abstract

Ubiquitin-conjugating enzyme E2T (UBE2T) is a member of the E2 family that mediates the ubiquitin-proteasome system and regulates gene expression. It is a major oncogene in several cancers such as lung cancer and breast cancer, while the potential functions of UBE2T in gastric cancer (GC) remains largely unknown. Here, we identified the roles of UBE2T in GC progression and its potential to act as a prognostic marker of GC. Our data demonstrated that UBE2T was significantly upregulated in gastric cancer tissues, and the high expression of UBE2T was significantly correlated with poor differentiation, high T classification, and poor prognosis. In vitro experiments indicated that UBE2T promoted cell proliferation and inhibited cell cycle arrest. In addition, we observed that UBE2T modulated cell mobility by inducing epithelial-mesenchymal transition. Collectively, these findings suggest that UBE2T plays an important role in the tumorigenesis of gastric cancer and could act as a potential independent prognostic factor for cancer therapy.

Keywords

UBE2T Gastric cancer Prognosis Proliferation 

Notes

Compliance with Ethical Standards

This study was supported by the Ethics Committee of Binhu Traditional Chinese Medicine Hospital. All patients agreed to participate in the study and gave written informed consent. The tissue microarray (TMA) containing 180 cases of gastric cancer specimens used in this study was purchased from Shanghai Outdo Biotech Inc, and the clinicopathological features were complete.

Conflicts of Interest

None

Supplementary material

13277_2016_5020_MOESM1_ESM.docx (14 kb)
Supplementary Table S1 (DOCX 14 kb)

References

  1. 1.
    Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singap Med J. 2014;55:621–8.CrossRefGoogle Scholar
  2. 2.
    Zilberstein B et al. Gastric cancer trends in epidemiology. Arq Gastroenterol. 2012;49:177–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Karimi P et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2014;23:700–13.CrossRefGoogle Scholar
  4. 4.
    Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol WJG. 2015;21:9838–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang WH et al. Outcomes of surgical treatment for gastric cancer patients: 11-year experience of a Chinese high-volume hospital. Med Oncol. 2014;31:150.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhai R et al (2014) miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151. Tumour Biol J Int Soc Oncodev Biol MedGoogle Scholar
  7. 7.
    Machida YJ et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23:589–96.CrossRefPubMedGoogle Scholar
  8. 8.
    Alpi A et al. UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: a basis for the regulation of FANCD2 monoubiquitination. Mol Cell Biol. 2007;27:8421–30.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Corson TW et al. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene. 2005;24:4741–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Hao J et al. Elevated expression of UBE2T in lung cancer tumors and cell lines. Tumour Biol J Int Soc Oncodev Biol Med. 2008;29:195–203.CrossRefGoogle Scholar
  11. 11.
    Kikuchi T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003;22:2192–205.CrossRefPubMedGoogle Scholar
  12. 12.
    Takata R et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:2625–36.CrossRefGoogle Scholar
  13. 13.
    Wen M et al. Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget. 2015;6:25226–39.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhai J et al. miR-129 suppresses tumor cell growth and invasion by targeting PAK5 in hepatocellular carcinoma. Biochem Biophys Res Commun. 2015;464:161–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Lin Y et al. Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36:7385–94.CrossRefGoogle Scholar
  16. 16.
    Tsunoda S et al (2014) Laparoscopic gastrectomy for remnant gastric cancer: a comprehensive review and case series. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer AssocGoogle Scholar
  17. 17.
    Takahashi Y et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2003;6:142–5.Google Scholar
  18. 18.
    Kochi M et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2000;3:177–86.Google Scholar
  19. 19.
    Hira A et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. Am J Hum Genet. 2015;96:1001–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rickman KA et al. Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of Fanconi anemia. Cell Rep. 2015;12:35–41.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Virts EL et al. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. Hum Mol Genet. 2015;24:5093–108.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ramaekers CH et al. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011;101:190–7.CrossRefGoogle Scholar
  23. 23.
    Kelsall IR et al. The Fanconi anaemia components UBE2T and FANCM are functionally linked to nucleotide excision repair. PLoS One. 2012;7, e36970.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ueki T et al. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 2009;69:8752–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Huang N et al. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget. 2015;6:15222–34.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Yoo YA et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011;71:7061–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Yang Y et al. C23 protein meditates bone morphogenetic protein-2-mediated EMT via up-regulation of Erk1/2 and Akt in gastric cancer. Med Oncol. 2015;32:76.CrossRefPubMedGoogle Scholar
  28. 28.
    Bullock MD et al. MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell Under Auspices Eur Cell Biol Organ. 2012;104:3–12.CrossRefGoogle Scholar
  29. 29.
    De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.CrossRefPubMedGoogle Scholar
  30. 30.
    Iwanaga R et al. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res BCR. 2012;14:R100.CrossRefPubMedGoogle Scholar
  31. 31.
    Che J et al. Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36:6559–68.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Hao Yu
    • 1
  • Pei Xiang
    • 1
  • Qi Pan
    • 1
  • Yijiao Huang
    • 1
  • Nanlan Xie
    • 1
  • Weimin Zhu
    • 1
  1. 1.Department of OncologyBinhu Traditional Chinese Medicine HospitalWuxiPeople’s Republic of China

Personalised recommendations